Protara Therapeutics, Inc.
TARAHealthcare|Biotechnology|US
$2.30
+0.17 (+7.98%)
DCF Value
$1.03
Tangible Book / Share
$2.24
Cash / Share
$2.02
Clinical Trials (7)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06910943 Study of Choline Chloride for Injection in Adolescent and Adult Patients With Intestinal Failure Receiving Long Term Parenteral Support | Choline Deficiency, Liver Injury | P2P3 | Recruiting | 129 | RCT, Double-blind | Choline Chloride for Injection, Placebo |
| NCT07480356 Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer | Bladder (Urothelial, Transitional Cell) Cancer, Non-Muscle Invasive Bladder Carcinoma | P3 | Recruiting | 284 | RCT, Open-label | TARA-002, Investigator's Choice of Intravesical Chemotherapy |
| NCT05951179 Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | Non-muscle Invasive Bladder Cancer | P2 | Recruiting | 131 | Open-label | TARA-002 |
| NCT05871970 Safety and Efficacy Study of Intracystic TARA-002 for the Treatment of Lymphatic Malformations in Participants 6 Months to Less Than 18 Years of Age | Lymphatic Malformation | P2 | Recruiting | 38 | Open-label | TARA-002 |
| NCT05085990 Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1b) | Non-muscle Invasive Bladder Cancer | P1 | Completed | 10 | Open-label | TARA-002 |
| NCT05085977 Safety and Toxicity Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer (Phase 1a) | Non-muscle Invasive Bladder Cancer | P1 | Completed | 12 | Open-label | TARA-002 |
| NCT05011370 Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition | Intestinal Failure-associated Liver Disease | Completed | 80 | — | — |